<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="495">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>28/09/2005</approvaldate>
  <actrnumber>ACTRN12605000536662</actrnumber>
  <trial_identification>
    <studytitle>Phase II study of allogeneic transplantation using transplant-lite conditioning regimes</studytitle>
    <scientifictitle>Phase II study to assess the safety and efficacy of allogeneic transplantation using transplant-lite conditioning regimes (Fludarabine and Melphalan) in patients with a diagnosis of a haematological malignancy or metastatic renal cancer who are considered unsuitable for a standard conditioning regime due to age, poor physical status or previous exposure to high dose chemotherapy/radiotherapy.</scientifictitle>
    <utrn />
    <trialacronym>Transplant LITE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic renal cancer</healthcondition>
    <healthcondition>Haematological malignancy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Fludarabine 25mg/kg day -7 to day -3 prior to Transplant Day 0.
Melphalan 120mg/m2 day -2 prior to Transplant Day 0.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Day 100 transplant related mortality defined by death due to graft failure, conditioning related toxicity, acute GVHD or infection. </outcome>
      <timepoint>At day 100.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Establishment of complete donor chimerism defined by VNTR (sex matched) or by VNTR and Y-chromosome FISH (sex mismatched)</outcome>
      <timepoint>At Day 28, 56, 84, 180, 270 and 365.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Assess the speed and completeness of donor cell engraftment.</outcome>
      <timepoint>Measured at Day 28, 56, 84, 180, 270, 365.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Assess the transplant related morbidity.</outcome>
      <timepoint>Measured at Day 28, 56, 84, 180, 270, 365.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Assess the incidence and severity of graft versus host disease.</outcome>
      <timepoint>Measured at Day 28, 56, 84, 180, 270, 365.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Assess progression free and overall survival.</outcome>
      <timepoint>Measured at Day 28, 56, 84, 180, 270, 365.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Summary of Patient/Donor Eligibility Criteria:1.  Diagnosis of haematological malignancy or metastatic renal cancer. 2.  ECOG performance status 0-2. 3.  Either a suitable HLA-identical sibling donor, fit for peripheral blood stem cell collection (cohort 1) or a suitable HLA-mismatched (single HLA mismatch) sibling donor, fit for peripheral blood stem cell collection, available HLA-identical (HLA-A,B,DRB1) unrelated donor or available HLA-mismatched (single HLA mismatch) unrelated donor (cohort 2).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>3/03/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr James Morton</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Brisbane and Women's Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bone Marrow and Stem Cell Transplant Unit, Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr James Morton</name>
      <address>Bone Marrow Transplantation (BMT) Unit
Cancer Care Services
Royal Brisbane and Women's Hospital
Level 5 Joyce Tweddell Building
Butterfield Street
Herston Brisbane QLD 4029</address>
      <phone>+61 7 36368111</phone>
      <fax />
      <email>James_Morton@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mrs Robyn Western</name>
      <address>Cancer Care Clinical Trials
Bone Marrow Transplantation (BMT) Department
Royal Brisbane and Women's Hospital
Level 5
Joyce Tweddell Building
Butterfield Street
Herston Brisbane QLD 4029</address>
      <phone>+61 7 36365378</phone>
      <fax />
      <email>Robyn_Western@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>